Endothelial progenitor cells in diabetic retinopathy


Published in:
Frontiers in endocrinology

Document Version:
Publisher's PDF, also known as Version of record

Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal

Publisher rights
Copyright: © 2014 Lois, McCarter, O’Neill, Medina and Stitt. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person’s rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
Diabetic retinopathy (DR) is a leading cause of visual impairment worldwide. Patients with DR may irreversibly lose sight as a result of the development of diabetic macular edema (DME) and/or proliferative diabetic retinopathy (PDR); retinal blood vessel dysfunction and degeneration plays an essential role in their pathogenesis. Although new treatments have been recently introduced for DME, including intravitreal vascular endothelial growth factor inhibitors (anti-VEGFs) and steroids, a high proportion of patients (~40–50%) do not respond to these therapies. Furthermore, for people with PDR, laser photocoagulation remains a mainstay therapy despite this being an inherently destructive procedure. Endothelial progenitor cells (EPCs) are a low-frequency population of circulating cells known to be recruited to sites of vessel damage and tissue ischemia where they promote vascular healing and re-perfusion. A growing body of evidence suggests that the number and function of EPCs are altered in patients with varying degrees of diabetes duration, metabolic control, and in the presence or absence of DR. Although there are no clear-cut outcomes from these clinical studies, there is mounting evidence that some EPC sub-types may be involved in the pathogenesis of DR and may also serve as biomarkers for disease progression and stratification. Moreover, some EPC sub-types have considerable potential as therapeutic modalities for DME and PDR in the context of cell therapy. This study presents basic clinical concepts of DR and combines this with a general insight on EPCs and their relation to future directions in understanding and treating this important diabetic complication.

Keywords: diabetic retinopathy, diabetic macular edema, endothelial progenitor cells, ischemia, proliferative diabetic retinopathy, retina, hematopoietic stem cells, vessels
FIGURE 1 | Fundus photographs obtained from patients with non-proliferative diabetic retinopathy (NPDR) (A) and proliferative diabetic retinopathy (PDR) (B). Note few hemorrhages and a cotton wool spot at the superior aspect of the macula in (A), and marked neovessels in the disc and macular exudation in (B).

FIGURE 2 | Fluorescein angiography obtained from the left eye of a patient with diabetic macular edema and PDR. Note drop out of perifoveal capillaries (A) with late leakage (B) and leakage from neovessels at the disc (A,B).

VASCULAR ABNORMALITIES

The pathological sequence of retinal vessel abnormalities in DR includes early and progressive thickening of the basement membrane and dysfunction and loss of endothelial cells, pericytes, and vascular smooth muscle [reviewed by Curtis et al. (21)]. Progressive capillary non-perfusion and ensuing ischemia in the diabetic retina may induce hypoxia-related up-regulation of cytokines and growth factors, such as vascular endothelial growth factor (VEGF) (22, 23), and this drives vasopermeability (DME) and/or abnormal neovascularization (21).

The diabetic milieu is highly damaging to the retinal capillary endothelium and this results in a significantly greater turnover of these cells when compared to non-diabetic equivalents (24). Exhaustion of endothelial cell replicative capacity and cells reaching their so-called Hayflick limit (25) means that the retinal vasculature in diabetic patients has impaired regenerative capacity. This underlines the progressive degenerative nature of DR in most patients.

RETINAL ISCHEMIA AND DIABETIC RETINOPATHY

Retinal ischemia is involved in the occurrence of the two major complications of DR, namely DME and PDR. Surprisingly, little is known about the natural history of retinal ischemia in DR and how it is modified by treatment. Ischemia can affect different areas of the retina; its implications with regard to the development of
complications of DR may depend on this topographic distribution and also on its extension. For example, a relatively small area of ischemia affecting the perifoveal capillaries (“ischemic maculopathy”) may have profound impact on vision. In contrast, a large area of midperipheral retinal ischemia may not produce an immediate change in sight but may trigger a neovascular response with development of PDR and poor longer term outcomes. In certain circumstances, very anterior (far peripheral) retinal ischemia, even if limited, may give rise to anterior segment neovascularization (rubeosis), including the development of neovascular glaucoma, and a more guarded prognosis. It is not clear why in some patients areas of retinal ischemia are mainly restricted to the macula, whereas in others the retinal vasculature is relatively intact at the macula but marked midperipheral retinal ischemia develops.

Clinically, retinal ischemia can be adequately identified, and its extension measured, by means of fundus fluorescein angiography (FFA) (Figure 3). For this imaging technique, a dye (fluorescein) is injected in a peripheral vein; images of the fundus are obtained as the dye circulates through the retinal blood vessels. Recently, new emerging technologies using wide-angle fundus cameras have become available (26, 27). These allow obtaining angiograms encompassing a 200-degree field of the retina in a single shot with a nearly complete visualization of the whole retinal vascular tree (Figure 4). Other new imaging techniques are being developed, such as differential phase-contrast swept-source optical coherence tomography (OCT), which allows visualization of retinal blood vessels without the need for injection of dyes (28–30).

Using FFA, spontaneous resolution of areas of retinal ischemia in DR has been observed (31), although the mechanisms underpinning re-perfusion have not been elucidated. Currently, no treatment has been identified that can reverse retinal ischemia in DR. For example, the current treatment for PDR, laser panretinal photocoagulation (PRP), aims at destroying the ischemic retina rather than at reperfusing it. Furthermore, progression of the disease can still be observed following PRP (Figure 5). As discussed below, circulating EPCs may play a role in vascular re-perfusion and tissue regeneration. In addition, delivery of these cells has emerged as an exciting potential therapeutic strategy for retinal ischemia in DR.

ENDOTHELIAL PROGENITOR CELLS

Endothelial progenitor cells (EPCs) are circulating cells believed to play an important role in tissue regeneration by promoting the repair of blood vessels and aiding in the re-perfusion of ischemic areas (32). EPCs generally account for only ~0.01% of circulating cells, although reported levels varied which may, once again,
reflect on the variability on the cells measured (33). Their origin remains somewhat uncertain; they may derive from hematopoietic stem cells in the bone marrow and/or highly specialized vascular stem cell niches in vessel walls or within the endothelium (34, 35). Controversy also exists with regard to the definition of an EPC. Pre-clinical and clinical investigations evaluating the therapeutic potential of EPCs have produced variable results, with some studies showing favorable outcomes whereas others failed to demonstrate success (36–39). It is likely that this variable response observed in EPC therapy relates, at least in part, to the use of a heterogeneous mixture of cells (not just EPCs) rather than being explained by the lack of therapeutic potential of a well-defined, efficacious EPC sub-type.

EPCs have been proposed as useful cell biomarkers of disease (40). For both therapeutic and biomarker investigations to be successful, it is essential that well-defined populations of EPCs are used. It would be advantageous if agreement among researchers in the EPC field could be reached, especially with regard to the definition and terminology used to refer these cells and their various sub-types. If the same type of EPCs were to be used for therapeutic or prognostic purposes by researchers, comparisons among studies and pooling of their data, required to increase the power of the evidence, would be possible, furthering the research into this exciting area. As discussed below, unfortunately, this has not been the case so far with regard to the existing literature on EPCs in DR.

DEFINING AN EPC

Groundbreaking research by Asahara et al. (32) first isolated endothelial cell progenitors from human peripheral blood using CD34 and Flk-1 (VEGF receptor 2, VEGF-R2) surface markers. They determined that these cells were able to differentiate into endothelial cells and incorporate into sites where active angiogenesis was taking place. Subsequent studies by other groups provided supporting evidence on the existence of circulating EPCs (41–44).

As pointed above, controversy exists with regard to how to define an EPC. In a very recent article, Basile and Yoder thoroughly reviewed this issue and provided a useful perspective on the characterization of EPCs (45). They suggested that evidence support the concept that endothelial colony-forming cells (ECFC), also known as outgrowth endothelial cells (OECs), display many features of circulating cells that are consistent with the original criteria set for an EPC. Basile and Yoder proposed the term pro-angiogenic hematopoietic cells (PACs) to refer to cells that are not in-fact endothelial progenitors but rather “adjuvants” in the process of vascular repair. Our previously identified myeloid angiogenic cells (MACs) would also fit with this definition. Thus, it is likely that different populations of adjuvants cells may exist (see below). The term “EPC” should not be used, hence, to refer PACs/MACs but be restricted to true EPCs (for many researchers, ECFCs).

ECFCs are retrieved with greater efficiency from cord blood compared with peripheral blood; indeed, the former source provides cells with higher proliferation rates and achieves significantly more population doublings than those from peripheral blood (46). A standard method for obtaining ECFCs is by in vitro culturing of the mononuclear fraction of blood at high density on Type 1 collagen-coated plates (47). Using this technique and depending on whether they are isolated from cord blood or peripheral blood, ECFCs colonies appear between 2 and 5 weeks and display a characteristic cobblestone-shaped morphology (Figure 6) (47). Research from our group using genome-wide transcriptomics, proteomics, and ultrastructural evaluation has demonstrated ECFCs intrinsic endothelial identity (48, 49). ECFCs have a remarkably high proliferative capacity in comparison with mature endothelial cells and maintain an endothelial phenotype with ex vivo long-term expansion (49). ECFCs have robust clonogenic potential, high telomerase activity, and in vitro and in vivo vessel formation ability (45). Single-cell cloning of ECFCs demonstrates a hierarchic regenerative potential with cells of high proliferative potential (HPP) and low proliferative potential (LPP) similar to what has been observed in hematopoietic stem cells (34, 44). Ingram et al. (44) previously demonstrated that cord blood-derived ECFCs possessed greater HPP (with concomitant enhancement of telomerase activity) than ECFCs isolated from peripheral blood. If ECFCs are to be utilized for regenerative...
In the context of medicine, it may be advantageous to isolate and use an ECFC sub-population with HPP in order to achieve maximum cell number expansion, if required.

ECFCs are positive for a range of endothelial cell markers, including VEGF-R2, VE-cadherin (CD144), CD31, CD105, CD146, and Tie2; negative for hematopoietic cell markers such as CD45, CD14, CD133, CD115, and demonstrate variable positivity to CD34 and CD117 (45, 50). Although evaluation of EPCs has been undertaken widely using a combination of the above cell markers by flow cytometry, as there is no specific antigen for ECFCs, *in vivo* and *in vitro* functional evaluations are required to identify specifically these cells. Thus, studies using only flow cytometry would be determining “putative” EPCs.

In contrast to ECFCs, PACs are CD34+ CD45+ CD133+ CD31+ CD14- CD235a- (45). Although circulating PACs may localize in a peri-vascular manner at sites of vascular injury, they are not able to integrate in the blood vessels as proper endothelial cells (45). PACs have LPP but they do appear to contribute to vascular repair by paracrine secretion of vasooactive molecules. Similar to PACs, MACs do not populate vessel walls but are pro-angiogenic. MACs are CD45+ CD14+ CD68+ CD163+ Tie2-, CD209− CD16- (51). Therefore, as much of the previously conducted work on “EPCs” was undertaken using cells that may not have fit strictly with the above definition of an ECFC and may have been only characterized by flow cytometry, data summarized below should be interpreted with caution.

**FUNCTIONAL PROPERTIES OF EPCs AND MODULATORY MECHANISMS**

Functionally, EPCs present characteristics of endothelial cells (50).Earlier studies emphasized the *in vitro* angiogenic potential of EPCs, their ability to integrate into pre-existing vessels and *de novo* tube formation (32, 43). Furthermore, several research groups, including our own, have demonstrated that EPCs possess *in vivo* potential for direct engraftment, aiding vascular repair and forming well-perfused vasculature in various *in vivo* models (32, 43). For example, the therapeutic potential of EPCs to treat retinal ischemia following intravitreal injection was shown in a mouse model of ischemic retinopathy in which ECFCs homed specifically to ischemic retina and integrated directly within the host vasculature (50). Importantly, these cells assisted in vascular remodeling by forming vascular tubes with subsequent reduction in the area of retinal ischemia and a concomitant increase in normal vasculature (50).

In response to hypoxia, EPCs have the ability to mobilize from their resident niche into the circulating blood and home to ischemic tissues. The mechanisms by which EPCs mobilize and specifically home to areas of ischemia are highly complex and incompletely understood. They involve a range of pathways and stimulatory factors such as EPO (52), VEGF (53), and G-CSF (54) but it also appears that signals released from apoptotic endothelial cells are important for EPC recruitment to sites of vascular damage (55). Since the homing process is hypoxia-mediated, it is unsurprising that HIF-1α appears to be crucial for EPC recruitment to sites of vascular insufficiency (56). On sensing low oxygen levels, HIF-1α induces transcription of SDF-1 and its receptor CXCR4, these known to be essential for EPC migration and adhesion to specific areas of ischemic damage (56). Blocking the CXCR4/SDF-1 signaling pathway inhibits EPC homing and results in their attenuated participation in promoting vascularization (57).

Several factors appear to influence the occurrence and circulating levels of EPCs. These include age (58) and gender (59) with younger women having higher numbers of EPCs. Physical activity also increases numbers of EPCs, especially intense exercise (60). A circadian rhythm on EPC release has been identified with higher levels of EPCs circulating in the morning than in the evening (61). Hypertension, diabetes, smoking habits as well as medications, including statins, angiotensin-converting enzyme inhibitors, and insulin may also affect the production and release of these cells into the circulation (40, 62).

**EPCs IN DIABETES AND DIABETIC RETINOPATHY**

Accumulating evidence supports the concept that both type 1 and type 2 diabetic patients have altered numbers of circulating EPCs (63–65) and, when isolated, show dysfunctional responses including impaired vasoreparative potential and premature senescence (65, 66). Conflicting results, however, have been reported with regard to the levels of circulating EPCs in people with diabetes. Thus, reduced (63), increased (67), or unchanged (68, 69) levels of EPCs compared with those observed in healthy age-matched volunteers have been found in previous studies using flow cytometry techniques. Similarly, although a reduced potential for EPCs to grow in cultures derived from monocytes obtained from peripheral blood was found by some investigators (64, 65, 70), others observed enhanced growth potential when EPCs were isolated from diabetic patients with PDR (67) (see below). Poor glycemic control, as determined by HbA1c levels, appears to be associated with a reduction in numbers of circulating EPCs whereas an adequate control of glycemia seems to increase their numbers (64). Beyond the presence of diabetes, a relatively scarce number of studies have been conducted evaluating EPCs specifically in patients with DR (Table 1) (67–69, 71–74). A summary of these follows.

**Clinical studies on EPCs and DR**

In a cross-sectional study including 60 type 2 diabetic patients with and without peripheral arterial disease and with and without severe NPDR and PDR (DR−/PAD− n = 15, DR−/PAD+ n = 30, DR+/PAD− n = 5, and DR+/PAD+ n = 10), Fadini and collaborators (69) identified reduced levels of CD34+ cells in patients with DR when compared with those without it. No differences in levels of CD34+/KDR+ (KDR = VEGF-R2) cells between these groups were, however, found. Patients with peripheral arterial disease had reduced levels of CD34+/KDR+ cells.

Lee and colleagues (73) evaluated, in a cross-sectional study, the concentration of circulating EPCs, defined as CD34+ cells or c-Kit+ cells, in a group of 45 type 2 diabetic patients and compared them with those observed in 15 age- and gender-matched control subjects. Patients were classified as having no DR (n = 15), NPDR (n = 15), or PDR (n = 15). Circulating CD34+ cell numbers were higher in diabetic patients compared with control subjects and increase with increasing staging of the disease (PDR > NPDR > no DR).

Brunner and collaborators (71) undertook a case-control cross-sectional study, which included 90 patients with type 1 diabetes, 15 controls, as well as healthy volunteers. The results showed that patients with diabetes had lower numbers of CD34+ cells compared with controls.
<table>
<thead>
<tr>
<th>Study</th>
<th>Patients</th>
<th>Controls</th>
<th>Study design</th>
<th>EPCs studied</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lombardo et al. (68)</td>
<td>DM type 2 = 54, Without angiopathy = 27, With angiography = 27</td>
<td>n = 24</td>
<td>Cross-sectional</td>
<td>Pre-EPC: CD34+/CD133+/CD117+ EPCs = CD34+/CD133+/VEGF-R2</td>
<td>Decreased late-EPCs in DM compared with controls</td>
</tr>
<tr>
<td>Zerbini et al. (74)</td>
<td>DM type 1 (n = 56), Without MVD = 47, With MVD = 17, DM ≤ 7 years = 20</td>
<td>n = 47</td>
<td>Cross-sectional</td>
<td>CD34+/CD45−/VEGFR2</td>
<td>No statistically significant difference on EPCs between groups</td>
</tr>
<tr>
<td>Brunner et al. (72)</td>
<td>DM type 2 = 126, Without MVD = 66, Without DR = 55, Mild NPDR = 19</td>
<td>none</td>
<td>Cross-sectional</td>
<td>CPCs = CD34+/CD133+ EPC = CD34+/CD133+/CD309+</td>
<td>MVD: Reduced numbers of EPCs with advanced stages of retinopathy  No MVD: no statistically significant changes in EPCs and mature EPCs; number of CPCs declined in mild NPDR, increase in PDR, decrease in high-risk PDR</td>
</tr>
<tr>
<td>Liu et al. (75)</td>
<td>DM type 2 = 40, With DR (severe NPDR and PAD) = 20</td>
<td>n = 20</td>
<td>Cross-sectional</td>
<td>CD34+/CD133+</td>
<td>Increased EPCs in DR compared with controls</td>
</tr>
<tr>
<td>Tan et al. (67)</td>
<td>DM type 1 = 9 and DM type 2 = 13 (undetermined = 1), With PDR = 23</td>
<td>n = 22</td>
<td>Cross-sectional</td>
<td>CD34+/CD45−</td>
<td>Increased EPCs in PDR compared with controls</td>
</tr>
<tr>
<td>Brunner et al. (71)</td>
<td>DM type 1 = 90, Without PDR = 30, Mild NPDR = 30, Moderate-severe NPDR = 10</td>
<td>n = 30</td>
<td>Cross-sectional</td>
<td>CPCs = CD34+/CD133+ EPC = CD34+/CD133+/CD309+, Mature EPC = CD34+/CD133+/CD309+/CD31+</td>
<td>When compared with diabetics with no DR, EPCs decreased in NPDR, EPCs increased in high-risk PDR, EPCs decreased in diabetics compared with control group</td>
</tr>
</tbody>
</table>

(Continued)
DM with no DR ($n=30$), mild NPDR ($n=30$), moderate to severe NPDR ($n=10$), mild to moderate PDR ($n=10$), and high-risk PDR ($n=10$). The study included an age-, gender-, and body-mass index-matched control group ($n=30$), CD34+/CD133+ (which they labeled “circulating progenitor cells” or “CPCs”), CD34+/CD133+/CD309+ (labeled as “EPCs”), and CD34+/CD133+/CD309+/CD31+ (labeled as “mature EPCs” or “mat-EPCs”) were measured. When compared with diabetic patients without DR, levels of CPCs, EPCs, and mat-EPCs were found to be reduced in NPDR; EPCs and mat-EPCs were found to be increased in PDR. EPC and mat-EPC number was reduced in patients with diabetes when compared with healthy subjects. As a more recent follow-up, this group expanded their observations to a group of 126 patients with type 2 diabetes, with or without macrovascular disease and with no DR ($n=55$), mild NPDR ($n=19$), moderate to severe NPDR ($n=16$), early PDR ($n=19$), and high-risk PDR ($n=17$) (72). In contrast to their previous findings, they failed to detect statistically significant differences in EPC numbers in patients with type 2 diabetes without macrovascular disease at different stages of DR. However, in patients with macrovascular disease, EPCs declined with advancing stages of retinopathy.

Liu and colleagues (75) examined type 2 diabetic patients with DR (severe NPDR and PDR, $n=20$), type 2 diabetic patients with peripheral arterial disease ($n=20$), and healthy age- and gender-matched volunteers (control group, $n=20$) and found increased levels of circulating EPCs in patients with DR when compared with the control group. EPCs were defined as CD133+ cells, as determined by flow cytometry. An increase in EPC-CFU (colony-forming units) was also observed in patients with DR. Serum levels of nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) were found to be increased in patients with DR and correlated with levels of circulating EPCs.

Tan and collaborators (67) undertook a study on a group of 23 diabetic patients, type 1 ($n=9$) and type 2 ($n=13$) ($n=1$ not determined) with PDR and 22 healthy controls. The great majority of patients (95%) had received PRP. They found that the number of circulating ECFCs, defined as CD34+/CD45− cells by flow cytometry, was increased in PDR. Furthermore, mononuclear cells obtained from patients who had PDR were more likely to grow ECFC colonies in culture than those obtained from healthy controls. ECFCs from patients with PDR demonstrated reduced migration (PDR $n=2$) and reduced incorporation into vascular tubes (PDR $n=3$) in vitro. Microarray analysis of ECFCs from patients with PDR ($n=2$) demonstrated up-regulation of thrombospondin-1 and tissue inhibitor of matrix metalloproteinases-3 (TIMP-3); western blotting confirmed increased levels of both proteins in ECFC lysates.

Lombardo and associates (68) did not find a significant reduction in the number of EPCs (CD34+/CD133+/VEGF-R2+) in patients with type 2 diabetes when compared with those from a group of healthy individuals (control group). Subsets of patients with diabetes with or without angiopathy were found to have significantly higher numbers of what was termed pre-EPCs (CD34+/CD133+/CD117+). However, numbers of CD31+/VEGF-R2+/VE-cadherin+ cells (CD144+), termed by the
authors “late-EPCs,” were reduced in patients with diabetes type 2 recently diagnosed (within 1 year of diagnosis) with no clinical evidence of angiopathy (n = 27) and in those with peripheral arterial occlusive disease and DR (severe NPDR or PDR) (n = 27) when compared with the control group (n = 24). The number of circulating endothelial cells, matured endothelial cells thought to sloughed off from the vascular intima, where increased in diabetic patients.

Zerbini and colleagues (74) evaluated three groups of type 1 diabetics, with long-standing (≥23 years; n = 17) and short-standing (≤7 years; n = 19) diabetes and no retinopathy and with NPDR (diabetes of ≤20 years standing; n = 20). A group of age- and gender-matched healthy volunteers were also included for each of the above (with n = 17, 12, and 18 subjects, respectively). No differences were found in levels of CD45−/CD34+/VEGFR2+ cells between the above different groups studied. However, the number of colonies formed in the Hill assay was increased in patients with NPDR when compared with those in the control group. Patients with milder retinopathy tended to form more colonies than patients with more severe retinopathy. In patients with long-standing diabetes and no retinopathy, the colony counts were similar to those in control subjects.

The interpretation of the previously presented findings is challenging. For instance, both high (67, 71) and low (69, 72) levels of circulating EPCs have been reported in patients with severe NPDR and PDR when compared with those in individuals with no or mild retinopathy and with healthy subjects without DM. It is possible that discrepancies observed may relate to methodological differences among studies, specifically, and as underlined above, the different criteria used to define an EPC. Other factors need to be taken into consideration. Some studies included small number of subjects (67–69, 73–75), especially when grouped in the different disease progression categories (68, 71–75), which may have had an effect on the statistical evaluation of the data (a sample power calculation was not given in any of the above studies). All published studies on the subject have been cross-sectional (67–69, 74, 75) and, subsequently, truly unable to evaluate the influence of changes in EPCs in relation to disease progression. Few addressed the relationship between number/function of EPCs and severity of DR (71–73) and none attempted to relate them to the presence/extension of retinal ischemia, as determined by using imaging modalities such as fluorescein angiography. As retinal ischemia would seem to be a main driver for eliciting a vasoregenerative response led by EPCs, correlating the latter with retinal ischemia would seem fundamental. In this regard, prospective longitudinal studies from our own laboratory are underway to address the relationship between retinal ischemia and the EPC response. As information with regard to flow cytometry techniques used in these studies was limited, variability in methodological aspects of flow cytometry could have also accounted for inconsistencies in the results observed.

**POtential USE OF EPCs IN DIABETIC RETINOPATHY**

Endothelial progenitor cells could be potentially used in the management of patients with DR with two different purposes: (1) as cell biomarkers or “prognosticators” and (2) as a potential therapy.

**EPCs AS BIOMARKERS OF DISEASE SEVERITY**

Endothelial progenitor cells have been proposed as useful biomarker for cardiovascular events and cancer progression (76, 77). In a similar manner, it is possible that EPC number/function could be used to predict which individuals may be at higher risk of losing sight from DME or PDR. Prospective adequately powered cohort studies would be needed to elucidate the potential use of EPCs as cell biomarkers for DME and PDR and take into account other risk factors and variables known to potentially affect retinopathy. It is possible that other cells besides those strictly defined as EPCs (for many, ECFCs) may be used for this purpose. As identification of ECFCs in culture requires a period of around 4–6 weeks, this strategy may be less practical and appealing than evaluating levels of other circulating cell types by flow cytometry. Research in this area could prove fruitful as predicting individuals at higher risk of visual loss would be extremely helpful to the currently overstretched DR screening programs and health care systems. This would allow a personalized follow-up strategy based on the individual’s risk of progression and would avoid close follow-up with the benefit to patients and health care systems.

**EPCs AS A POTENTIAL THERAPY TO TREAT DR**

The potential use of EPCs to treat DR is exciting but extensive work is required before they could be introduced in clinical practice. Firstly, the type of cell(s) to be used and the number of cells required should be determined. If a cell, alone, were to be used for therapeutic purposes, those with the highest reparative potential (i.e., ECFCs) may be chosen. Although not the subject of this review, pericyte progenitor cells (PPCs) have been recently recognized (78, 79). As both, endothelial cells and pericytes are affected in DR, it would seem reasonable to consider the possible administration of both progenitors in order to treat this vascular disorder. Recently, Lee and co-workers (80) demonstrated that CD34− cells may modulate the inherent characteristics and behavior of ECFCs. They showed in vitro that ECFCs arising from cultures in which CD34+ and CD34− cells are present (to which they referred to as “hybrid ECFCs”) have higher proliferation capacity and slower senescence than those ECFCs grown in cultures lacking CD34− cells (which they referred to as stem-ECFCs). The later, however and importantly, demonstrated higher endothelial cell differentiation. Both cell types (hybrid ECFCs and stem-ECFCs), expressed ECFC surface markers, including CD133, VEGFR2, CXCR4, and c-kit) but did not expressed hematopoietic lineage markers (CD11b, CD14, CD45). Before CD34− cells are used to condition ECFCs prior to treatment (80) it would be important to determine that these ECFCs do not have an increased ability to form “neovessels.” Whereas in other organs “neovascularization” may be beneficial, for instance in the heart, this would not be the case in the retina where “revascularization” or “healing” of pre-existing blood vessels rather than neovascularization should be sought. Other cells may be also considered. As PACs are likely to act as adjuvants in the process of “vascular regeneration,” further consideration to administering these, in addition, should be given. However, the possibility for PACs to develop into pro-inflammatory cells, which could have potentially a deleterious effect in the retina, should be cautiously balanced.
Secondly, the number of cells required would need to be estimated. It is likely that it would depend on the route of administration selected as well as on the stage of disease at which patients are planned to be treated. The route of administration will need to be carefully chosen. Local delivery into the eye by means of intravitreal injections would be an option, as many clinical trials using anti-VEGF therapy (Ranibizumab, Bevacizumab, and Afibercept) have demonstrated their safety even when administered monthly. However, considering the fact that DR often affects similarly both eyes and that DM is a systemic disorder in which other organs besides the eye are affected and may benefit from this therapy, systemic administration should not be ruled out. Systemic administration, if safe, could be given repeatedly, if required, and at an early stage of disease.

Thirdly, the population most likely to benefit from treatment with EPCs should be defined. EPCs could be used in an attempt to re-vascularize areas of retinal ischemia in patients who have already developed retinal vessel dropout as determined by fluorescein angiography. They could be used also to improve retinal vessel function in patients with increased vessel permeability and subsequent DME with or without retinal ischemia being present. If the balance between beneficial effects and side effects were to be appropriate, EPCs could be used even at very early stages of retinopathy, before marked retinal vessel abnormalities occurred in an attempt to abort progression to sight threatening complications. Alternatively, maneuvers aimed at increasing levels of circulating endogenous EPCs, by stimulation of the bone marrow and other EPC niches, and their homing to sites where needed (i.e., retina) would be an appealing option.

Fourthly, the most appropriate outcome measures that would allow treatment effects to be determined in clinical trials should be sought. For instance, if ECFCs adequately incorporate into damaged retinal blood vessels in ischemic retina oxygen levels in retinal veins may be expected to drop, as it has been shown that there is increased oxygen saturation in people with DR (85, 86), which may relate, at least partially, by the poor distribution of blood to retinal tissue result of capillary dropout. Fluorescein angiography and, in the future, when fully developed for clinical use, differential phase-contrast swept-source OCT may be able to provide adequate information with regard to ECFCs incorporation to retinal vessel walls by demonstrating the presence of capillaries in retinal areas were prior to treatment were not present and, in the case of the former, by demonstrating improve circulation in previously ischemic areas. Retinal functional studies, such as multifocal ERG responses, may be able to determine improved responses in those areas where revascularization takes place.

Lastly but importantly, potential side effects of the treatment will need to be carefully evaluated. Data from available completed clinical trials, however, suggests that ECFCs should be safe for clinical use.

**CONCLUSION**

Available data suggests EPCs are essential on maintaining retinal vessel integrity and homeostasis. While some patients seem to have inherent regenerative capacity, the molecular and cellular basis for this has not been demonstrated. It seems likely that high levels of reparative cells could underpin less risk of DR progression. However, the precise role of EPCs in DR remains to be determined. Experimental and adequately powered prospective cohort clinical studies are required to better understand the possible role of EPCs in the occurrence and progression of this disease. The possibility of using EPCs as cell biomarkers of the sight threatening complications of DR, namely DME and PDR and as cell therapy is an exciting one. Given the complexity of DM and DR, with multiple factors modulating disease progression, a joint effort by multidisciplinary research teams is likely to be needed in order to achieve this goal.

**ACKNOWLEDGMENTS**

The authors would like to thank Ms Anne Ramsey for her invaluable expertise obtaining the images that illustrate this manuscript.

**REFERENCES**


Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.